Key Points
- Insider sale: Director Ramiro Ribeiro sold 42,544 shares on Jan. 5 at an average price of $17.10, a transaction worth $727,502.40 disclosed in an SEC filing.
- Earnings miss and weak fundamentals: Eyepoint reported a Q3 EPS of ($0.85) vs. ($0.77) expected, with revenue of $0.97M, a negative net margin of 485.95% and negative ROE, and analysts forecast ~-2.13 EPS for the year.
- Mixed analyst sentiment but positive price target: The stock trades near $17.37 (1-year range $3.91–$19.11) with a $1.44B market cap; analysts average a "Buy" rating and a consensus price target of $29.25, while ratings range from "strong-buy"/"outperform" to one "sell."
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 42,544 shares of Eyepoint Pharmaceuticals stock in a transaction on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Eyepoint Pharmaceuticals Trading Up 3.0%
EYPT stock opened at $17.37 on Thursday. Eyepoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $19.11. The firm has a market cap of $1.44 billion, a PE ratio of -5.81 and a beta of 1.63. The business's 50-day moving average price is $15.25 and its two-hundred day moving average price is $12.89.
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%.The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $3.33 million. On average, analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.
Wall Street Analysts Forecast Growth
EYPT has been the topic of several research analyst reports. Royal Bank Of Canada increased their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, November 6th. TD Cowen raised Eyepoint Pharmaceuticals to a "strong-buy" rating in a report on Friday, December 19th. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, November 25th. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $29.25.
Read Our Latest Research Report on EYPT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Eyepoint Pharmaceuticals by 1,636.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company's stock valued at $27,000 after buying an additional 2,733 shares during the last quarter. State of Alaska Department of Revenue bought a new position in Eyepoint Pharmaceuticals during the third quarter worth $50,000. Russell Investments Group Ltd. acquired a new position in Eyepoint Pharmaceuticals in the third quarter valued at $76,000. Tower Research Capital LLC TRC grew its holdings in Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after acquiring an additional 5,967 shares during the period. Finally, R Squared Ltd bought a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth about $100,000. Institutional investors and hedge funds own 99.41% of the company's stock.
Eyepoint Pharmaceuticals Company Profile
(
Get Free Report)
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
